Foundation Medicine

Explore this news: www.foundationmedicine.com/press-releas...

Proud to support the National Cancer Institute & @eaonc.bsky.social ComboMATCH initiative. Now with the inclusion of our blood-based biomarker test, results will continue to help determine trial eligibility for patients who may benefit from the effectiveness of biomarker-targeted cancer treatment.

March is Colorectal Cancer Awareness Month

March is Colorectal Cancer Awareness Month. We are proud to support the colorectal cancer community in spreading greater awareness around prevention, early detection and access to resources for this disease.

Foundation Medicine is looking forward to engaging with the latest research in genitourinary (GU) cancers at #GU26. New #research from the team showcases new insights around MTAP loss in GU cancers. Stop by booth 8 to meet with us.

Learn more: bit.ly/4qWCunb

Interested in learning more? Connect with our team at booth 8, click the link here to find time: bit.ly/4rEi9El

We’re presenting several #ProstateCancer posters at #GU26 covering insights on HRDsig, TP53 mutations & the clinical validity of Foundation Medicine’s tissue-based companion diagnostic test to identify BRCA+ & other HRR+ patients w/ metastatic castration-sensitive prostate cancer

Foundation Medicine will be at ASCO GU - February 26-28, 2026 in San Francisco, CA. Booth 8.

Miss. Not. One. at #GU26! Connect with our team at booth 8 & discover how advancements in comprehensive genomic profiling can help healthcare providers make confident, personalized treatment decisions for their patients with advanced cancer. Learn more: spkl.io/63323AQt6F

Deep dive into gene fusions and how testing for fusions with DNA and RNA is so important for their detection in our latest “Genomics in Moments” video. Watch below.

Recognizing Gallbladder and Bile Duct Cancer Awareness Month

February is Gallbladder and Bile Duct Cancer Awareness Month. By supporting education around these rare cancers —and continuing to spread awareness—we can help encourage conversations, drive greater understanding and provide resources to those affected by these diseases.

New publication - DNA and RNA-Based Next-Generation Sequencing for Companion Diagnostic Rearrangement Detection In Solid Tumors

Background of research

First key takeaways slide of research

Second key takeaways slide of research

New #research from our team explored the potential benefits of concurrent RNA-based next-generation sequencing (NGS) with DNA-based NGS to help improve genomic rearrangement detection. Learn more from the study published in The Oncologist: spkl.io/63320AsJVy

Click the link to explore our programming and to request time to meet with us at the meeting – we hope to see you in San Diego: www.foundationmedicine.com/event/founda...

Foundation Medicine is heading to the 10th Annual Liquid Biopsy for Precision Oncology Summit! With a full schedule of events, including a plenary session, dinner program & booth exhibit, our team is looking forward to connecting on the latest innovations in liquid biopsy.

True or false: methyl thioadenosine phosphorylase (MTAP) loss is a rare alteration? Healthcare providers, if you’re not seeing MTAP loss in ~1 in 10 solid tumors, you may be missing out on clinical trial opportunities. Explore our abstract for more: spkl.io/63324AU56K

New publication - Circulating tumor DNA as a biomarker in early phase clinical trials

Introduction of research

Key takeaways 1 of research

Key takeaways 2 of research

Explore a new review article published in spkl.io/63328AWm9w – “Circulating tumor DNA as a biomarker in early phase clinical trials.” Read more: spkl.io/63320AWm9j

Read more about our new collaboration with ConcertAI: www.foundationmedicine.com/press-releas...

"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."

Visit Foundation Medicine at booth 8. Learn more: bit.ly/49cAgdI

New #study at #GI26 utilizes genomic data from Foundation Medicine to explore the relationship between ERBB2 amplification and gene- and protein-level expression in GI cancers to understand combined predictive value.

Attending the meeting? Stop by booth 8 to connect with our team! Click here to learn more: bit.ly/4jveRQl

Our team is excited to attend #GI26 and to join oncology leaders in discussing the latest innovations shaping gastrointestinal (GI) cancer care. #Research highlights we’re looking forward to sharing include four new abstracts on MTAP loss in GI cancers.

Join Foundation Medicine in San Francisco at #GI26 - booth 8. January 8-10, 2026.

Connect with Foundation Medicine at #GI26! Learn more about the latest advancements in comprehensive genomic profiling at booth 8. Learn more & schedule a meeting: spkl.io/63320Amj1M

Foundation Medicine at Endpoints @ #JPM26

Join us for the session “2026: The new priorities in oncology R&D and diagnostics” featuring Foundation Medicine CEO, Dan Malarek at this year’s @endpts.com at #JPM26 event. Learn more: spkl.io/63321AlaTD

New Publication - Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer

Publication Highlights

New #ProstateCancer research published in @CCR_AACR – “Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer”: spkl.io/63320Acu2w

Behind the Manuscript: ctDNA monitoring & blood TMB in a pan-tumor setting Learn more about how Foundation Medicine researchers and collaborators leveraged real-world data to evaluate changes in circulating tumor DNA (ctDNA) tumor fraction and blood tumor mutational burden to assess treatment response to immune checkpoint inhibitors in a pan-tumor setting. Hear more from Candice Francheska Tambaoan, MPH, Data Scientist II at Foundation Medicine, on how this research shows the utility that ctDNA monitoring can have in assessing treatment response and serving as a complement to imaging.

#Research leveraged real-world data to evaluate changes in ctDNA tumor fraction & blood tumor mutational burden to assess treatment response to immune checkpoint inhibitors in a pan-tumor setting. Learn more: spkl.io/63328AcuwI

New Blog from Foundation Medicine - Driving Innovation Together: Helping Biopharmaceutical Partners Deliver Breakthroughs

Innovations in precision medicine require collaboration, actionable insights and a commitment to advancing cutting-edge science. Explore how we are helping our #biopharma partners turn scientific promise into progress in our new blog: spkl.io/63329AcBID

Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies - PubMed <span><i>MTAP</i> is a key biomarker in precision oncology; this work describes the clinical outlook for these patients within the community-oncology setting. These insights can inform future study design, as <i>MTAP</i>-directed therapies continue their development.</span>

Explore this new study at the link here: pubmed.ncbi.nlm.nih.gov/41348984/

#DYK that MTAP loss reporting can vary across NGS vendors? In a study from Sarah Cannon Research Institute, Foundation Medicine’s tissue NGS detected MTAP loss in about 1 out of 10 solid tumors. It’s not a rare biomarker – even though it can be hard to identify accurately.

Our team is excited to present two new pieces of research in #breastcancer that show the importance of robust homozygous gene loss reporting in BRCA1/2 and PTEN. Learn more from Foundation Medicine at #SABCS25 - booth 1342: spkl.io/63323A9iEF

New Publication - Coverage of Actionable Alterations In Non-Small Cell Lung Cancer by Hybrid Capture-Based FoundationOne®CDx Compared With Amplicon-based Oncomine™ DX

New #research in non-small cell lung cancer reflects a simulated, retrospective analysis of oncology biomarker assays. Read this publication in The Oncologist –spkl.io/63322A9Vdk

Foundation Medicine at SABCS 2025 - December 9-12, 2025, Booth 1342

Join us at #SABCS25, December 9-12. Visit booth 1342 to learn how Foundation Medicine’s comprehensive genomic testing portfolio can help inform treatment options for advanced breast cancer patients. Learn more: spkl.io/63325AgY6S